Unlocking the Power of Carbohydrate Click-based Sugar-conjugated Vaccine

The expression of cell surface carbohydrate antigens correlates extremely well with cancer development, and the expression of specific antigens is mainly associated with cancer transformation status. To better understand the antigenic immune system, CD BioGlyco provides clients with high-quality GlycoCLICK™-based Vaccine Development service. We rationalize the development of efficient sugar-conjugated vaccines through antigenic structure design and synthesis.

Tumor-Associated Carbohydrate Antigens (TACAs): Promising Immune Targets

CD BioGlyco offers the following several antigen vaccine development services:

CD BioGlyco has a professional talent team and advanced instruments. For the carbohydrate click-based sugar-conjugated vaccine, we have rich development experience, and always ensure high quality and efficient service quality.

• Chemical synthesis
  We provide chemical synthetic antigens services using click chemistry. Meanwhile, our investigators rapidly synthesize glycoconjugate vaccines by Huisgen1,3-dipole cycloaddition at room temperature. Moreover, we provide purification and characterization services.
• Modification of TACAs in anti-tumor vaccine
  To overcome the low immunogenicity of TACAs, we provide modification services such as O-acetylated modification, fluorine-containing modifications, etc.
• Immune assessment
  • Enzyme-linked immunosorbent spot (ELISPOT) assay
  • Serological analysis
  • Animal model
  • Immunization program

  • Enzyme-linked immunosorbent assay (ELISA) analysis
  • Flow cytometry analysis
  • Fluorescence-activated cell sorter (FACS) analysis
  • Cell surface reactivity assay

Fig.1 Schematic diagram of carbohydrate click-based sugar-conjugated vaccine development service. (CD BioGlyco)

Publication

Advantages of Us

• The synthetic services we provide have mild reaction conditions, high yield, simple examination, strong selectivity, and strong specificity.
• We effectively overcome the complexity of isolating tumor antigens by clicking reaction-synthesized antigens from natural sources.
• Our professional R&D team has high professional quality and industry experience to ensure the quality and progress of the project.

Frequently Asked Questions

• Why choose the carbohydrate antigen as a target for vaccine development?
  Although TACAs are overexpressed on the surface of cancer cells, they are also present in small amounts on normal cells and are therefore regarded as autoantigens by the immune system. In TACAs, carbohydrate antigens are indigenous antigens and are not easily recognized as foreign molecules by the immune system. TACA-based vaccines recognize natural antigens expressed on cancer cells and selectively promote their clearance. At CD BioGlyco, we provide effective TACA-based anticancer vaccine development services through precise structural design.
• TACAs antigens fail to induce T cell-mediated immunity and alone only weakly activate B-cells. How to play the role of immunotherapy?
  • Binding TACAs to protein or peptide carriers containing established T-cell epitopes is an effective immunization method for developing vaccines against carbohydrates. Antigen-presenting cells (APCs) capture and internalize the conjugated vaccine as it enters the body and cleaves it into peptides. The peptide epitopes are then presented to the cell surface as complexes of molecules. These complexes present antigens to T cells to promote their activation. Activated T cells release cytokines that promote B cell multiplication to produce IgG antibodies.
  • Immunization through the use of adjuvants in vaccines. For example, activating toll-like receptors (TLRs) on the surface of macrophages and stimulating cytokine release from APCs induce the onset of innate immunity.

CD BioGlyco has rich experience with GlycoCLICK™-based vaccine development service. Our service staff have mature industry experience, effectively solving the doubts in vaccine development. Please feel free to contact us.

• Triazole Skeleton-based Vaccine Development Service
• Multivalent Glycopeptide-lipopeptide Vaccine Development Service